Follow-up report on pulmonary mucosa-Associated lymphoma in a patient with von Hippel-Lindau disease

Bukola A. Olarewaju; Judy B. Tejon; Mayowa A. Osundiji

doi:10.1093/jscr/rjae619

Follow-up report on pulmonary mucosa-Associated lymphoma in a patient with von Hippel-Lindau disease

Bukola A. Olarewaju, Judy B. Tejon, Mayowa A. Osundiji (Lead / Corresponding author)

Civil Engineering

Research output: Contribution to journal › Article › peer-review

38 Downloads (Pure)

Abstract

With the increasing opportunities for medical management of von Hippel-Lindau (VHL)-related lesions, fundamental questions are arising regarding the possibilities of the FDA-Approved medication (Belzutifan) to delay the progression of other non-VHL-related tumors that are not requiring urgent surgical interventions. We present a follow-up report on a VHL patient, with a co-morbid history of pulmonary mucosa-Associated lymphoid tissue lymphoma, who was initially described in the clinical scientific literature ~10 years ago. This patient's case highlights some of the challenges for some VHL patients with comorbid non-VHL-related tumors and potential opportunities for targeted support.

Original language	English
Article number	rjae619
Number of pages	2
Journal	Journal of Surgical Case Reports
Volume	2024
Issue number	10
DOIs	https://doi.org/10.1093/jscr/rjae619
Publication status	Published - 5 Oct 2024

Keywords

lymphoma
tumor
von Hippel-Lindau

ASJC Scopus subject areas

Surgery

Access to Document

10.1093/jscr/rjae619Licence: CC BY

Final Published VersionFinal published version, 193 KBLicence: CC BY

Cite this

@article{c2d0b5d71891467d994767b07e7079e5,

title = "Follow-up report on pulmonary mucosa-Associated lymphoma in a patient with von Hippel-Lindau disease",

abstract = "With the increasing opportunities for medical management of von Hippel-Lindau (VHL)-related lesions, fundamental questions are arising regarding the possibilities of the FDA-Approved medication (Belzutifan) to delay the progression of other non-VHL-related tumors that are not requiring urgent surgical interventions. We present a follow-up report on a VHL patient, with a co-morbid history of pulmonary mucosa-Associated lymphoid tissue lymphoma, who was initially described in the clinical scientific literature \textasciitilde{}10 years ago. This patient's case highlights some of the challenges for some VHL patients with comorbid non-VHL-related tumors and potential opportunities for targeted support.",

keywords = "lymphoma, tumor, von Hippel-Lindau",

author = "Olarewaju, \{Bukola A.\} and Tejon, \{Judy B.\} and Osundiji, \{Mayowa A.\}",

note = "Publisher Copyright: {\textcopyright} 2024 Published by Oxford University Press and JSCR Publishing Ltd. ",

year = "2024",

month = oct,

day = "5",

doi = "10.1093/jscr/rjae619",

language = "English",

volume = "2024",

journal = "Journal of Surgical Case Reports",

issn = "2042-8812",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Follow-up report on pulmonary mucosa-Associated lymphoma in a patient with von Hippel-Lindau disease

AU - Olarewaju, Bukola A.

AU - Tejon, Judy B.

AU - Osundiji, Mayowa A.

PY - 2024/10/5

Y1 - 2024/10/5

N2 - With the increasing opportunities for medical management of von Hippel-Lindau (VHL)-related lesions, fundamental questions are arising regarding the possibilities of the FDA-Approved medication (Belzutifan) to delay the progression of other non-VHL-related tumors that are not requiring urgent surgical interventions. We present a follow-up report on a VHL patient, with a co-morbid history of pulmonary mucosa-Associated lymphoid tissue lymphoma, who was initially described in the clinical scientific literature ~10 years ago. This patient's case highlights some of the challenges for some VHL patients with comorbid non-VHL-related tumors and potential opportunities for targeted support.

AB - With the increasing opportunities for medical management of von Hippel-Lindau (VHL)-related lesions, fundamental questions are arising regarding the possibilities of the FDA-Approved medication (Belzutifan) to delay the progression of other non-VHL-related tumors that are not requiring urgent surgical interventions. We present a follow-up report on a VHL patient, with a co-morbid history of pulmonary mucosa-Associated lymphoid tissue lymphoma, who was initially described in the clinical scientific literature ~10 years ago. This patient's case highlights some of the challenges for some VHL patients with comorbid non-VHL-related tumors and potential opportunities for targeted support.

KW - lymphoma

KW - tumor

KW - von Hippel-Lindau

UR - https://www.scopus.com/pages/publications/85206336870

U2 - 10.1093/jscr/rjae619

DO - 10.1093/jscr/rjae619

M3 - Article

C2 - 39376720

AN - SCOPUS:85206336870

SN - 2042-8812

VL - 2024

JO - Journal of Surgical Case Reports

JF - Journal of Surgical Case Reports

IS - 10

M1 - rjae619

ER -

Follow-up report on pulmonary mucosa-Associated lymphoma in a patient with von Hippel-Lindau disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this